This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

This study has been completed.
Information provided by (Responsible Party):
Jeffrey Fink, University of Maryland Identifier:
First received: April 16, 2009
Last updated: December 1, 2014
Last verified: December 2014
This study examines patients with chronic kidney disease-related anemia and measures changes in the metabolism of the heart using FDG/PET scanning, before and 6 months after their health-care provider has initiated anemia management therapy with the FDA-approved drug darbepoetin alfa (Aranesp), which is approved for chronic kidney disease-related anemia. The investigators hypothesize that the heart has abnormal metabolism with the anemia of chronic kidney disease but this improves after correction of this anemia with darbepoetin alfa.

Condition Intervention Phase
Cardiomyopathy Chronic Kidney Disease Anemia Drug: Darbepoetin alfa Phase 4

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: A Study to Evaluate the Effect of the Treatment of Anemia on Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

Resource links provided by NLM:

Further study details as provided by Jeffrey Fink, University of Maryland:

Primary Outcome Measures:
  • Change to myocardial glucose uptake as measured by fluoro-deoxy-D-glucose (FDG) positron emission tomography (PET) scan from pre-treatment compared to 6 months after anemia therapy initiation. [ Time Frame: 6 months ]

Enrollment: 20
Study Start Date: May 2008
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Darbepoetin alfa
    Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol
    Other Name: Aranesp

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study population consists of individuals being followed for their chronic kidney disease (CKD) at one of the Nephrology/Early Renal Insufficiency Clinics at the Baltimore, Maryland VA Medical Center and are being considered for erthropoietin therapy for anemia related to CKD.

Inclusion Criteria:

  • Participant must receive care at the VAMHCS (VA Hospital) in Baltimore
  • Diagnosed with CKD stage 3 to 5 (eGFR of 60 ml/min/1.73m2) and not expected to initiate renal replacement therapy within 6 months
  • Anemia related CKD.
  • The last 2 serum hemoglobin (Hb) values less than 11.0 gm/dl but greater than 8.0 gm/dl
  • Greater than 18 years of age
  • Assessed to be clinically stable by the clinician

Exclusion Criteria:

  • Need for hemodialysis, peritoneal dialysis, or transplantation at the time of enrollment or projected to start within 6 months after enrollment
  • Low functional capacity including inability to walk a flight of stairs with a bag of groceries (NYHA Class III/IV Heart Failure)
  • Prior erythropoietic agents within last 12 weeks
  • TSAT < 15% and not receiving the recommended dose for iron deficiency
  • Uncontrolled hypertension defined as greater than 180 mm Hg systolic or 110 mm Hg diastolic
  • Potentially "brittle" diabetes with the propensity for symptomatic hypoglycemia after a 6 hour fast
  • New diagnosis or ongoing therapy for Cancer
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00883415

United States, Maryland
Baltimore VA Medical Center
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
University of Maryland
Principal Investigator: Jeffrey C Fink, MD MS University of Maryland School of Medicine and Baltimore VA
  More Information

Responsible Party: Jeffrey Fink, Professor, Nephrology (primary); Epidemiology (secondary), University of Maryland Identifier: NCT00883415     History of Changes
Other Study ID Numbers: HP-00041025
Amgen ISS#20061907
Study First Received: April 16, 2009
Last Updated: December 1, 2014

Keywords provided by Jeffrey Fink, University of Maryland:
chronic kidney disease

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Hematologic Diseases
Urologic Diseases
Renal Insufficiency
Heart Diseases
Cardiovascular Diseases
Darbepoetin alfa
Hematinics processed this record on September 21, 2017